BMS-986012 is a Monoclonal Antibody owned by Bristol-Myers Squibb, and is involved in 3 clinical trials, which are ongoing.

BMS-986012 binds to fucosyl-GM1 on cancer cells and elicits both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells.

The revenue for BMS-986012 is expected to reach a total of $201m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BMS-986012 NPV Report.

BMS-986012 was originated by Medarex and is currently owned by Bristol-Myers Squibb.

BMS-986012 Overview

BMS-986012 is under development for the treatment of solid tumor like relapsed or refractory small cell lung cancer. The drug candidate is administered intravenously as a solution. The drug candidate targets cell expressing fucosyl GM1, a sphingolipid monosialoganglioside and tumor-associated antigen (TAA), is overexpressed on the surface of many cancer cells. The drug candidate is developed based on UltiMAb human antibody development system.

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.

Quick View – BMS-986012

Report Segments
  • Innovator
Drug Name
  • BMS-986012
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.